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•	 nodal staging in 
Lung Cancer: A Risk 
stratification Model for 
Lymph nodes Classified as 




OPTOMETRY AND VISION SCIENCE
Copyright © 2014 American Academy of Optometry
nodes in the derivation set (n = 196) and the validation 
set (n = 133) revealed that independent predictors of 
malignancy were lymph node standardized uptake 
value, the standardized uptake value ratio between the 
lymph node and primary tumor, and heterogeneous 
echogenicity during sonography. The model stratified 
lymph nodes into low risk with a score of less than 
equal to 1 and high risk with a score of greater than 
equal to 2. Lymph nodes in the derivation and validation 
sets from the low-risk group (n = 141 of 142 and 94 
of 96, respectively) were further proven to be benign; 
those from the high-risk group (n = 35 of 54 and 
24 of 37, respectively) were malignant. A negative 
predictive value of 99.3% and 97.9% in the derivation 
and validation sets, respectively, was achieved using 
this model. The findings indicated that this is a robust 
risk stratification model for identifying patients who 
could seek treatment directly following a negative 
endobronchial ultrasound-guided transbronchial needle 
aspiration assessment or otherwise require further 
staging analysis. (p. 126) 
•	 supportive Care in Lung 
Cancer: Milestones Over 
the Past 40 Years
This article describes the evolution of supportive care 
in lung cancer over the past 40 years, with an overall 
review of its developments, milestones, and future 
research and practice. Studies on the importance of 
supportive care to clinical practice has increased since 
the 1980s, encompassing identification of supportive 
care in lung cancer, symptoms and their management, 
psychosocial aspects and coping with lung cancer, 
issues related to quality of life and patient-reported 
outcomes, best supportive care versus treatment, 
smoking cessation before and after diagnosis of lung 
cancer, and service delivery models. The authors 
acknowledged that more work is warranted for the 
future and new research to meet the needs of lung 
cancer patients. They also highlighted the role and 
continuous efforts of the International Association of the 
Study of Lung Cancer in achieving the goals. (p. 10) 
In ThIs Issue
The authors restrospectively evaluated patients with primary lung 
cancer and only negative lymph nodes determined by endobronchial 
ultrasound-guided transbronchial needle aspiration in the United 
Kingdom, to develop and validate a risk stratification model, which 
will categorize these negative lymph nodes into low-risk and high-
risk groups of a false-negative diagnosis. The analysis of lymph 
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•	 Adjuvant Chemotherapy 
Is Associated with 
Improved survival after 
esophagectomy with-
out Induction Therapy 
for node-Positive 
Adenocarcinoma
The authors set out to evaluate predictors of 
adjuvant chemotherapy (AC) use and the impact 
of AC on survival in 1694 patients in the National 
Cancer Database treated with R0 esophagectomy 
without induction therapy for node-positive (pN+) 
adenocarcinoma. They found that only half of the 
patients were given AC (51.6%), 70.7% of which also 
received radiation. The lack of AC use was significantly 
associated with older age (adjusted odds ratio [AOR] 
0.58/decade; p < 0.001), longer travel distance (AOR 
0.78 of 100 miles; p = 0.03), and complications related 
to surgery (CRS; AOR 0.45; p < 0.001). Compared 
with patients without AC, those treated with AC showed 
significantly improved 5-year survival (24.2% versus 
14.9%; p < 0.001). Multivariate analysis showed a 
significant association between AC and improved 
survival (hazard ratio 0.67; p = 0.008). They also 
found that radiation in addition to AC did not result in 
a survival benefit (p = 0.35). AC use also substantially 
improved survival of those with CRS when compared 
with those without CRS or AC (p = 0.016), despite 
CRS was associated with poor long-term survival and 
lower chance of receiving AC. All in all, the findings 
demonstrated significant survival advantage from AC in 
patients with pN+ adenocarcinoma after esophagectomy, 
even in those with complications, who should also be 
strongly considered for AC. (p. 181) 
which is the current standard prognostic tool in lung 
cancer. The results validated both the CCP score and 
the prognostic score as independent predictors of lung 
cancer mortality in this patient population (CCP score 
after adjustment for clinical variables: hazard ratio [HR] 
= 1.46, p = 0.0050; prognostic score: HR = 2.01, p = 
2.8 × 10−11 in the full cohort, and HR = 1.67, p = 0.00027 
in stage I patients). A threshold of the 85th percentile 
of the prognostic score could significantly differentiate 
5-year lung cancer survival between low-risk and high-
risk patients (82% versus 65%; p = 3.8 × 10−7). Taken 
together, the prognostic score demonstrated substantially 
enhanced discrimination power with the added 
prognostic value of the CCP signature to pathological 
stage in risk stratification for lung cancer death. This 
model could guide decision making on treatments 
optimal for resected early-stage lung cancer patients, for 
instance adjuvant chemotherapy for those with a high 
risk for recurrence. (p. 67) 
•	 Validation of a Molecular 
and Pathological Model for 
5-Year Mortality Risk in 
Patients with early-stage 
Lung Adenocarcinoma
To validate a cell cycle progression (CCP) score in stratifying early-
stage lung cancer patients for high risk of 5-year cancer mortality 
postsurgical resection, Bueno et al. analyzed 31 proliferation 
genes in formalin-fixed paraffin-embedded surgical tumor samples 
from 650 patients with stage I and II adenocarcinoma without 
adjuvant chemotherapy. Furthermore, they assessed the prognostic 
significance of the combination of the CCP score and pathological 
stage (the prognostic score) compared with pathological stage alone, 
Image credit: NCI.
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nodules (volume <100 mm3 or diameter <5 mm) were 
not associated with lung cancer, whereas large nodules 
were associated with 16.9% (volume ≥300 mm3) or 
15.2% (diameter ≥10 mm) of lung cancer probability, 
requiring immediate diagnostic evaluation. Volume 
doubling times of less than equal to 400 days were 
associated with 9.9% of developing lung cancer, and this 
measurement was only associated with intermediate-
sized nodules (volume 100–300 mm3). The sensitivity 
and specificity of the simulated American College of 
Chest Physician management protocol were 90.9% 
and 87.2%, respectively, whereas those of a diameter-
based protocol were 92.4% and 90.0%, respectively, 
and those of a volume-based protocol were 90.9% and 
94.9%, respectively. The findings indicated that nodule 
management protocols based on these thresholds outdid 
the simulated American College of Chest Physician 
protocol performance.
Horeweg N, van Rosmalen J, Heuvelmans MA, et al. 
Lung cancer probability in patients with CT-detected 
pulmonary nodules: a prespecified analysis of data from 
the NELSON trial of low-dose CT screening. Lancet 
Oncol 2014.
•	 Genomic Alterations in 
the RB Pathway Indicate 
Prognostic Outcomes 
of early-stage Lung 
Adenocarcinoma
mutation profile was found in the mucinous subtype. 
The findings suggest that patients with early-stage 
lung adenocarcinoma harboring mutations in the 
RB pathway might benefit from additional clinical 
interventions targeting the pathway, in contrary to the 
current treatment guidelines that recommend follow-up 
without adjuvant therapy postresection. In addition 
to the discovery of potential prognostic markers, this 
study shed light on more defined molecular profiles of 
different subtypes for better personalized treatment for 
early-stage lung adenocarcinoma patients.
Choi S, Kim HR, Sung CO, et al. Genomic 
alterations in the RB pathway indicate prognostic 
outcomes of early-stage lung adenocarcinoma. Clin 
Cancer Res 2014; doi:10.1158/1078-0432.ccr-14–0519.
ReseARCh WATCh
•	 Lung Cancer Probability 
in Patients with Computed 
Tomography (CT)-Detected 
Pulmonary nodules: A 
Prespecified Analysis of 
Data from the neLsOn 
Trial of Low-Dose CT 
screening
In this prespecified analysis, Horeweg et al. aimed to determine the 
association of nodule diameter, volume, and volume doubling time 
with the probability of developing lung cancer within 2 years of 
a low-dose computed tomography (CT) (LDCT) scan, using data 
from the NELSON trial. Eligible participants were aged 50 to 75 
years, with smoking history of 15 cigarettes or more/day for more 
than 25 years, or 10 cigarettes or more/day for more than 30 years, 
or quit smoking less than 10 years ago. They were randomized 
to LDCT with increasing intervals or no LDCT. The analysis of 
9681 noncalcified nodules detected by LDCT showed that small 
The authors sought to determine the association of genomic 
alterations on clinical outcomes by assessing copy number 
variations and the complete exomes of lung adenocarcinomas 
in 247 Korean patient tumor samples and paired normal 
tissues. Genomic alterations in the RB pathway were found to 
be significantly associated with shorter disease-free survival 
in patients with stage I and II lung adenocarcinomas with 
and without adjuvant chemotherapy (p = 0.025 and 0.020, 
respectively). The observations were confirmed in the validation 
cohort (p = 0.017 and 4.0 × 10−3, respectively). None of these 
associations were found in stage III or IV patients, regardless of 
adjuvant chemotherapy. The analysis also revealed the association 
between specific genomic mutation and histological subtypes. 
In particular, a very heterogeneous mutation profile was found 
in solid and micropapillary subtypes, whereas the most unique 
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arm showed a trend of improved median overall survival 
compared with the gefitinib arm (12.4 versus 9.6 months; 
p = 0.077). Quality of life evaluation was not significantly 
different between arms. No new treatment-related adverse 
events were observed. They also found that Scorpion 
amplification refractory mutation system was superior 
to direct sequencing in excluding false-negative cases. 
The authors concluded that this was the first report 
that demonstrated second-line pemetrexed resulted in 
significant improvement in progression-free survival and a 
better overall survival trend when compared with gefitinib 
for EGFR wild-type advanced nonsquamous non–small-
cell lung cancer patients. The authors suggested those with 
unknown EGFR status in the second-line setting to test 
for EGFR mutation to receive the optimal regimen, and 
amplification refractory mutation system is recommended 
as a standard test for the detection.
Zhou Q, Cheng Y, Yang J-J, et al. Pemetrexed 
versus gefitinib as a second-line treatment in advanced 
non-squamous non-small-cell lung cancer patients 
harbouring wild-type EGFR (CTONG0806): a 
multicenter randomized trial. Ann Oncol 2014; 
doi:10.1093/annonc/mdu463.
•	 Pemetrexed Versus 
Gefitinib as a second-Line 
Treatment in Advanced 
nonsquamous non–small-





This multicenter phase II randomized trial assessed the efficacy and 
safety of second-line pemetrexed versus second-line gefitinib in 157 
patients with locally advanced or metastatic nonsquamous non–small-
cell lung cancer harboring wild-type epidermal growth factor receptor 
(EGFR). Patients with prior platinum-based chemotherapy were 
randomized to pemetrexed or gefitinib. The primary end point, median 
progression-free survival, of the pemetrexed arm was 4.8 months 
versus 1.6 months in the gefitinib arm (p < 0.001). The pemetrexed 
•	 Intratumor heterogeneity 
in Localized Lung 
Adenocarcinomas 
Delineated by Multiregion 
sequencing
could identify most of the known driver mutations in 
this disease. Furthermore, their findings at a median 
follow-up of 21 months after surgery showed that a 
significantly larger proportion of subclonal mutations 
(40%) in one or a few regions of the tumor was found 
in all three patients with relapse compared with 17% of 
these mutations in those without relapse. This implies 
an association between a larger fraction of subclonal 
mutations and higher risk of postsurgical relapse. The 
authors cautioned that a larger study in early-stage 
lung adenocarcinomas is required to confirm these 
findings, which could provide insights on future patient 
stratification for increased risk of relapse and clinical 
studies of therapeutic intervention for postsurgical 
relapse.
Zhang J, Fujimoto J, Zhang J, et al. Intratumor 
heterogeneity in localized lung adenocarcinomas 
delineated by multiregion sequencing. Science 
2014;346:256–259.
Zhang et al. conducted whole-exome sequencing on 48 regions 
from 11 resected localized non–small-cell lung adenocarcinomas. 
They found intratumor heterogeneity in all tumors; an average of 
76% of all mutations and 20 of 21 known cancer gene mutations 
were identified in all regions of the same tumor. This suggests 
that sequencing one region of a localized lung adenocarcinoma 
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acquiring driver mutations, suggesting that initiation of 
chromosomal instability later in tumor evolution could 
hamper effort in targeting truncal driver events. This 
finding in conjunction with the observation of potential 
long NSCLC tumor latency before clinical detection 
supports the continued efforts in optimizing methods 
for early detection. The findings of subclonal, regionally 
separated driver mutations and the heterogeneity of 
genomic instability reflect challenges in therapeutic 
intervention for NSCLC. Longitudinal studies are 
warranted to detect drivers and origins of subcloncal 
diversification that lead to metastasis and the underlying 
mechanism that contributes to poor patient outcome.
de Bruin EC, McGranahan N, Mitter R, et al. 
Spatial and temporal diversity in genomic instability 
processes defines lung cancer evolution. Science 
2014;346:251–256.
•	 The Biological and Clinical 
effects of smoking by 
Patients with Cancer and 
strategies to Implement 
evidence-Based Tobacco 
Cessation support
comorbid disease. Therefore, cancer patients should 
be accurately identified for their tobacco use and be 
provided with structured tobacco cessation support. 
This study also discusses variables in the design and 
implementation of a sustainable tobacco cessation 
program. The authors concluded that tackling tobacco 
use in cancer patients could dramatically improve 
overall outcomes from cancer treatment with lowered 
treatment-associated adverse events, treatment failure, 
and comorbid disease, as well as prolonged survival.
Warren GW, Sobus S, Gritz ER. The biological and 
clinical effects of smoking by patients with cancer 
and strategies to implement evidence-based tobacco 
cessation support. Lancet Oncol 2014;15:e568–e580.
with progressive disease (p < 0.0001) but lower 
after treatment in those with partial response and 
stable disease (p < 0.0001). The level of Hsp90α 
protein was also strongly associated with tumor size 
postchemotherapy (378.83 versus 227.23 ng/ml; p 
< 0.0001). Plasma Hsp90α protein level more than 
56.33 ng/ml was found to predict lung cancer with 
a specificity of 78.70% and a sensitivity of 72.18%, 
which was comparable with carcinoembryonic 
antigen and CYFRA21-1 for lung cancer diagnosis. 
The findings suggest that plasma Hsp90α protein 
level could be a valuable diagnostic biomarker and 
could improve diagnostic sensitivity if combined with 
carcinoembryonic antigen and CYFRA21-1. It could 
also predict patient response to chemotherapy.
Shi YK, Liu XQ, Lou JT, et al. Plasma levels of heat 
shock protein 90 alpha associated with lung cancer 
development and treatment responses. Clin Cancer Res 
2014; doi:10.1158/1078-0432.ccr-14–0174.
•	 Plasma Levels of heat 
shock Protein 90 Alpha 
Associated with Lung 
Cancer Development and 
Treatment Responses
This study recruited 2247 individuals with lung cancer or who 
were healthy controls to evaluate the diagnostic and predictive 
values of plasma heat shock protein 90 alpha (Hsp90α) levels 
in lung cancer. Plasma Hsp90α protein levels were analyzed by 
enzyme-linked immunosorbent assay and associated with tumor 
stages and treatment responses. Significantly higher average 
plasma Hsp90α protein levels were found in lung cancer patients 
versus healthy controls (p < 0.0001) and in advanced lung cancer 
(stages III–IV) versus early-stage lung cancer (stages I–II; p < 
0.001). The plasma level of Hsp90α protein was significantly 
different between pre- and postsurgery patients (134.33 versus 
99.81 ng/ml; p = 0.0062). In patients treated with chemotherapy, 
plasma Hsp90α protein level was higher after treatment in those 
•	 spatial and Temporal 
Diversity in Genomic 
Instability Processes 
Defines Lung Cancer 
evolution
de Bruin et al. uncovered driver mutations before and after 
subclonal diversification after sequencing of 25 spatially distinct 
regions from seven resected non–small-cell lung cancer (NSCLC). 
Pronounced intratumor heterogeneity was detected in copy number 
alterations, translocations, and APOBEC cytidine deaminase 
activity–associated mutations. An increase in APOBEG-associated 
mutations over time was found in tumors from smokers, with 
relatively decreasing smoking-related mutations even with 
maintained carcinogen exposure. This may reflect the activity of 
the mutagenesis process and the selective advantage of the acquired 
mutations. Former smokers showed genome-doubling within a 
smoking-signature context before subclonal diversification but after 
Warren et al. reviewed a total of 622 publications (1990–2012) 
in a meta-analysis of known biological and clinical effects of 
continued smoking in cancer patients who received chemotherapy 
or radiotherapy. They found that smoking deteriorates clinical 
outcomes in cancer patients, partly through tumorigenic pathways 
activation, and partly through physiological changes that result 
in cancer treatment complications and continued development of 
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neWs In BRIeF
•	 novartis and Bristol-Myers 
squibb Collaborated 
in studies of novel 
Immunotherapy in 
Combination Treatments 
for non–small-Cell Lung 
Cancer
Novartis has joined forces with Bristol-Myers Squibb in phase I/
II studies to investigate the efficacy and safety of three molecularly 
targeted compounds, Zykadia, INC280 and EGF816 in combination 
with the investigational PD-1 immune checkpoint inhibitor, and 
Opdivo (nivolumab) in patients with non–small-
cell lung cancer (NSCLC). Zykadia (ceritinib) is an 
FDA-approved treatment for anaplastic lymphoma 
kinase-positive metastatic NSCLC that are resistant 
to crizotinib. INC280 is a potent and selective c-MET 
inhibitor, and EGF816 is a potent third-generation 
EGFR tyrosine kinase inhibitor against T790 mutations. 
Both INC280 and EGF816 are under ongoing phase 
I/II trials for NSCLC. The collaboration allows 
investigation of the highly potent anaplastic lymphoma 
kinase inhibitor ceritinib and other key compounds with 
a promising novel immunotherapy that might lead to 
potential new therapeutic interventions for patients with 
NSCLC.  
Image credit: FDA.
•	 American society of 
Clinical Oncology 
endorses Guideline for 
Molecular Testing to select 
Lung Cancer Patients for 
epidermal Growth Factor 
Receptor and Anaplastic 
Lymphoma Kinase 
Inhibitor Treatment
by an American Society of Clinical Oncology Expert 
Panel. The guideline consists of 37 recommendations 
(evidence grade A or B), expert consensus opinions, 
and suggestions covering five major areas: the timing of 
conducting molecular testing, methods of performing 
EGFR and ALK testing, routine testing of other genes 
in lung adenocarcinoma, and the implementation of 
molecular testing. Reported in the Journal of Clinical 
Oncology by Leighl et al., the guidelines recommend 
EGFR and ALK testing to all lung adenocarcinoma 
patients, regardless of gender, race, and smoking status. 
Different testing methods that meet certain technical 
requirements can be used by laboratories, provided 
guidelines are followed in specimen processing, testing 
validation, quality assurance, and result turnaround times. 
The review panel also underscored evolving areas in ALK 
testing methods, molecular testing in selected populations, 
and new targetable genetic alterations.   
The College of American Pathologists, the International Society 
for the Study of Lung Cancer, and the Association of Molecular 
Pathologists guideline on molecular testing to select lung cancer 
patients for epidermal growth factor receptor (EGFR) and anaplastic 
lymphoma kinase (ALK) tyrosine kinase inhibitor therapy has been 
endorsed by the American Society of Clinical Oncology after a review 
Image credit: NCI.





The anti-PD-1 pembrolizumab has been granted 
Breakthrough Therapy Designation by the FDA for 
advanced non–small-cell lung cancer patients, who 
are epidermal growth factor receptor mutation–
negative, and anaplastic lymphoma kinase (ALK) 
rearrangement–negative, and whose disease 
progressed following platinum-based chemotherapy. 
Pembrolizumab blocks the interaction of PD-1 with 
its ligands PD-L1 and PD-L2, resulting in antitumor 
immune response. The designation is based on the 
updated findings from the phase IB KEYNOTE-001 
trial presented at the European Society of Medical 
Oncology 2014 annual meeting.   
Image credit: FDA.
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•	 2014 Chicago 
Multidisciplinary 
symposium in Thoracic 
Oncology: Lung 
Adenocarcinoma 
staging Based On 2011 
International society for 
the study of Lung Cancer/
ATs/eRs Classification—A 
Pooled Analysis of 
Adenocarcinoma in situ 
and Minimally Invasive 
Adenocarcinoma
which were lung adenocarcinoma staged according to the 
2011 International Society for the Study of Lung Cancer/
ATS/ERS classification. Their findings, presented at the 
2014 Chicago Multidisciplinary Symposium in Thoracic 
Oncology, showed that there was no statistically significant 
difference in the survival rates between patients with 
AIS and MIA subtypes. The analysis included 14 eligible 
studies of 642 patients with a median age of 67.5 years, 
61% female and 37% smokers, comprising 296 AIS cases 
and 278 MIA cases. Between the AIS and MIA groups, 
the 5-year DFS rate was 96.5% versus 96.6% (p = 0.2) and 
the 5-year OS rate was 97.1% versus 96.9% (p = 0.4). For 
the whole population, the 5-year DFS rate was 97.7% and 
the 5-year OS rate was 97.9%. The results raised questions 
on the necessity to subclassify these tumors based on the 
proposed 2011 International Society for the Study of Lung 
Cancer/ATS/ERS classification.
Behera et al. conducted a systematic analysis of published studies from 
2011 to 2014 in the MEDLINE, Embase, and Cochrane databases 
to evaluate the differences in disease-free survival (DFS) and overall 
survival (OS) between adenocarcinoma in situ (AIS; no invasion) 
and minimally invasive adenocarcinoma (MIA; ≤0.5 cm invasion), 
•	 2014 Chicago 
Multidisciplinary symposium 
in Thoracic Oncology: switch 
Maintenance with sunitinib 
(s) in Advanced non–small-
Cell Lung Cancer—An 
Alliance (CALGB 
30607), Randomized, 
Placebocontrolled Phase III 
Trial
progression-free survival compared with the placebo 
arm (4.3 versus 2.8 months; hazard ratio = 0.58; p = 
0.0004). The same was observed in both squamous and 
nonsquamous histology (both p = 0.01). Both arms 
showed similar overall survival (11.7 versus 11.2 months; 
hazard ratio = 1.08; p = 0.63). Treatment termination 
was mostly as a result of disease progression in the 
placebo arm (89.7% versus 48.5%) and adverse events 
in the sunitinib arm (26.7% versus 4.1%). Grade 3/4 
toxicities in more than 5% of patients were reported, more 
frequently in the sunitinib arm. Significantly higher rate of 
subsequent therapy was found in the placebo arm versus 
the sunitinib arm (78% versus 62%; p = 0.01). This study 
met its primary end point, with a significantly prolonged 
progression-free survival for the advanced NSCLC 
patients given sunitinib switch maintenance therapy.
This study by Socinski et al. aimed to compare switch maintenance 
with sunitinib versus placebo for stage IIIB/IV non–small-cell lung 
cancer (NSCLC) patients after first-line chemotherapy. The analysis 
included 210 patients of median age 66 years, more than half were 
male and with ECOG PS 1, approximately 88% stage IV, and mostly 
current or past smokers. Adenocarcinoma accounted for 45.7%, 
followed by squamous (33.2%), undifferentiated NSCLC (13.5%), 
and large cell (4.3%). The sunitinib arm showed overall improved 
•	 2014 Chicago 
Multidisciplinary 
symposium in Thoracic 
Oncology: A Decade Of 
“50 In 5”—Maturing 
stereotactic Body 
Radiotherapy Outcomes 
For Medically Inoperable 
early-stage Lung Cancer 
at Cleveland Clinic Over 
10 Years
of 79.0% versus 75.4%, distant metastasis-free rates of 
49.5% versus 56.7%, disease failure-free rates of 37.3% 
versus 34.3%, and overall survival rates of 18.3% versus 
20.3%. There was no significant difference in failure rates 
between central and noncentral tumors for all parameters. 
Rates of local, lobar, and regional nodal failure were 11.2%, 
4.1%, and 13.5%, respectively. Overall rate of any toxicity 
was 13.0%, which mostly were of grade less than equal to 
2 and none were grade 4 or 5. The findings highlighted a 
remarkable long-term, local control with lung SBRT using 
50 Gy in five fractions in medically inoperable patients with 
early-stage non–small-cell lung cancer, regardless of tumor 
location in the lung and with minimal toxicities. The authors 
hope to further investigate SBRT in a clinical trial in fit and 
operable lung cancer patients with cancer localized within 
the lung to provide a more minimally invasive procedure 
than surgery.
Videtic et al. conducted a 10-year analysis of an institutional stereotactic 
body radiotherapy (SBRT) registry in medically inoperable non–small-
cell lung cancer patients treated with 50 Gy in five fractions. There were 
340 lesions treated in 300 patients of the study, of which 15% received 
greater than equal to two SBRT treatments. The patients were of median 
age of 74 years and were followed-up for a median of 17.4 months, with 
46.7% alive at the time of follow-up. Patients with central tumors versus 
noncentral tumors at 5 years post-treatment achieved local control rates 
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neWs FROM The InTeRnATIOnAL 
sOCIeTY FOR The sTuDY OF 
LunG CAnCeR TOBACCO 
COnTROL COMMITTee
•	 Good news: smoking Rates Declining
When you follow this link, try to stay focused on 
the headline. The article is surrounded by alarming 
distractions of the modern media kind involving plastic 
surgery, celebrities with the initial K, and pictures of 
princes next to, if not in, bikinis. However, if one pays 
attention to the matter at hand, the news is good. In 
the United Kingdom, smoking rates are falling and the 
star demographic group is the under 25s. The statistics 
include an 18.7% smoking rate for adults (down from 
19.8%) with sharp falls in young women, by 10% in 
a year. The fall in smoking rates goes with falls in 
drinking and teenage pregnancy (a hat-trick perhaps) 
and has been linked by some to the advent of social 
media keeping the kids at home. The data come from the 
UK Office for National Statistics, a cohort of 270,000 




•	 2014 Chicago 
Multidisciplinary 
symposium in Thoracic 
Oncology: Postoperative 
Radiotherapy Is Associated 
with Better survival in 
non–small-Cell Lung 
Cancer with Involved n2 
Lymph nodes
Mikell et al. reviewed a retrospective cohort of 2115 
patients, from the National Cancer Data Base, who 
had resected non–small-cell lung cancer with involved 
N2 (pN2) nodes treated with adjuvant chemotherapy 
and postoperative radiotherapy (PORT), excluding 
those received cobalt-60, nonbeam radiotherapy, or 
neoadjuvant radiotherapy. PORT was given to 43.4% 
of the patients, whereas 56.6% did not receive it. 
The analysis showed improved overall survival in the 
PORT arm versus no PORT (42 versus 38 months; p = 
0.045). The same effect was observed in multivariate 
and inverse probability of treatment weighting Cox 
models (hazard ratio = 0.87; p = 0.026 and hazard ratio 
= 0.89; p = 0.046, respectively). Multivariate analysis 
demonstrated that better overall survival was associated 
with female sex, adenocarcinoma histology, higher 
income, urban/rural versus metropolitan setting, lower 
T stage, one to two involved lymph nodes (LNs) versus 
greater than equal to three, higher number of examined 
LN, and younger age (all p < 0.05). No interaction 
was observed between PORT benefits and number of 
involved LN (p = 0.615). The findings reinforce the 
value of PORT for resected non–small-cell lung cancer 
with involved pN2 in addition to chemotherapy.
9Copyright © 2014 by the International Association for the Study of Lung Cancer
•	 e-Cigarettes: Two Reports 
from the Conference of 
the Parties
WHO/FCTC. The public health dispute and controversy 
over smoking cessation, smoking “normalization,” 
unregulated advertising, and the role of tobacco 
companies in manufacture and marketing of ENDs is 
also addressed. These two reports do provide regulatory 
considerations and options for governments to consider 
based on available evidence. These regulatory options 
include prohibition of unsupported health claims, 
restriction of ENDs use in public places, application 
of mandatory advertising codes similar to tobacco and 
alcohol products and regulation of product design. This 
report is a welcome oasis of calm in a difficult and at 
times, passionate debate. Figure 8. 
A study from the University of Liverpool in the United 
Kingdom looks at the use of e-cigarettes in a local Stop 
Smoking Service. Study data drawn from questionnaires 
and interviews were presented at the National Cancer 
Research Institute Cancer Conference on November 
2–5. The investigators found that most e-cigarette users 
were female and over 40 years, most participants viewed 
e-cigarettes as a short-term aid to cessation, and, from 
the subset who were interviewed, most disapproved of 




Two reports have recently been released on ENDs, or Electronic 
Nicotine Delivery Systems, the most prominent of which is the 
e-cigarette. Both reports arise from the Sixth Session of the 
Conference of the Parties (COP) (to the World Health Organization 
[WHO] Framework Convention on Tobacco Control [FCTC]) 
held on October 13–18, 2014, Moscow. The COP is the governing 
body of the WHO FCTC and can be explored at www.who.int. 
The reports are similar, one from the FCTC and one from WHO 
itself. The WHO report (reference FCTC/COP/6/10 Rev.1) can 
be found through the WHO Web site, following links to the Sixth 
Session’s documents. The points made in these two reports appear 
measured and appropriate with particular reference to long-term 
health risks of ENDs, their efficacy in smoking cessation, and 
possible interference with existing tobacco control efforts of the 
Figure 8. Image credit: FDA.
snIPPeTs FROM ACTIOn 
TO QuIT
•	 Canada Considers Banning 
Flavored Tobacco
A report on the Web site www.canada.com (search 
on this site for “menthol cigarettes”) tells of a recent 
Canadian health ministers meeting in Banff to look at 
banning flavoring tobacco as a way of deterring entry 
into smoking for young people. Did you know there are 
or were bubble-gum and blueberry flavored cigarettes? 
They were banned in 2010; menthol cigarettes, 
described in the report as “tobacco with training 
wheels,” are now in the cross-hairs.
•	 south Korea Tobacco Tax 
Rise
A report released on October 8 (www.thediplomat.com/
tag/smoking/) details the effect of a proposed tobacco 
tax hike in South Korea. The planned tax would nearly 
double the cost of a pack of cigarettes from the equivalent 
of US$2.32 to $4.20. Even though the tax proposal has 
yet to be passed at a legislative level, it seems to have 
had some effect already with a doubling in the number of 
people registering for public smoking clinics (even more 
in chain smokers and those over 40 years). The proposed 
legislation also includes restrictions on advertising and 
requirements for warnings on products. According to the 
report, South Korea’s adult male smoking rate is 41%; 
this move aims to help reduce the rate to 29% by 2020.
